Clinical trials: APL
Acute Promyelocytic Leukemia
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
Summary Acute promyelocytic leukemia is defined by a characteristic morphology (AML FAB M3/M3v), by the specific translocation t(15;17) and its molecular correlates (PML/RARa and RARa/PML).
- Trial name
- NCT00504764
- Testing
- Arsenic Trioxide, Autologous Transplantation, Allogenic Transplantation
- Where
- 86 sites in Spain
- Volunteers
- 60 people
- Sponsor
- PETHEMA Foundation
Preoxygenation
Can we Improve Preoxygenation by Using Adjustable Pressure Limiting Valve (APL) ?
The aim of this study is to investigate the effects of setting airway pressure release valve (APL valve) on the anesthesia workstation to 5 cmH2O during spontaneous breathing on preoxygenation.
- Trial name
- NCT04010279
- Testing
- preoxygenation with 100% O2, fresh gas flow rate 12 L/minute
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kahramanmaras Sutcu Imam University
Acute Promyelocytic Leukemia
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR-positive for the PML-RARα transcript and less than 18 years of age.
- Trial name
- NCT04793919
- Testing
- Mylotarg, Arsenic Trioxide, All-trans retinoic acid
- Where
- 31 sites in Belgium, Czechia and 10 more
- Volunteers
- 89 people
- Sponsor
- Associazione Italiana Ematologia Oncologia Pediatrica
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
A Safety Study of SGN-CD33A in AML Patients
This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) administered as a single agent and in combination with a hypomethylating agent (HMA).
- Conditions
- Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia
- Trial name
- NCT01902329
- Testing
- HMA, SGN-CD33A
- Where
- 14 sites in United States
- Volunteers
- 195 people
- Sponsor
- Seagen Inc.
APL
Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
Based on the current treatment with retinoic acid (ATRA) and arsenic (As), most patients with APL achieved long-term survival. There are few patients relapsed and became refractory to the RA and As treatment.
- Trial name
- NCT05881265
- Testing
- Chidamide+venetoclax
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Acute Promyelocytic Leukemia With PML-RARA
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
This phase II trial studies how well tretinoin and arsenic trioxide with or without gemtuzumab ozogamicin works in treating patients with previously untreated acute promyelocytic leukemia.
- Trial name
- NCT01409161
- Testing
- Arsenic Trioxide, Gemtuzumab Ozogamicin, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 151 people
- Sponsor
- M.D. Anderson Cancer Center
Tumour
Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL
This study was a single-arm, open study. After the screening period, arsenic-resistant APL patients were treated with interferon α-2b, arsenic and venetoclax. The efficacy (ORR) and safety were evaluated.
- Trial name
- APL (NCT06450145)
- Testing
- interferon α-2b
- Where
- 2 sites in China
- Volunteers
- 15 people
- Sponsor
- Zhejiang Provincial People's Hospital
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
This randomized phase II trial studies azacitidine with or without entinostat to see how well they work compared to azacitidine alone in treating patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
- Trial name
- NCT00313586
- Testing
- Azacitidine, Entinostat, Laboratory Biomarker Analysis
- Where
- 234 sites in United States
- Volunteers
- 197 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myelocytic, Acute
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
The study will compare the efficacy of the 2 treatments in intermediate and high-risk APL patients in achieving first hematological complete remission and molecular remission.
- Trial name
- NCT00962767
- Testing
- gemtuzumab ozogamicin, ATRA plus 6-MP and MTX
- Volunteers
- 168 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Acute Promyelocytic Leukemia With PML-RARA, t(15;17)
Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia
This clinical trial studies how well simplified patient care strategy works in decreasing early death in patients with acute promyelocytic leukemia.
- Trial name
- NCT03253848
- Testing
- Simplified Patient Care Strategy, Laboratory Biomarker Analysis
- Where
- 294 sites in United States, Puerto Rico
- Volunteers
- 202 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Leukemia
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00053144
- Testing
- cytarabine, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Promyelocytic Leukemia, Adult Acute
RWE of 1st Line Treatment With ATO/ATRA for Adult APL
This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of acute promyelocytic leukemia (APL) patients in the first line with arsenic trioxide and all…
- Trial name
- NCT04897490
- Testing
- Evaluation of first line treatment with ATO/ATRA outcome
- Where
- 6 sites in Argentina
- Volunteers
- 50 people
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
Brain and Central Nervous System Tumors, Leukemia
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00458744
- Testing
- talotrexin, chemotherapy
- Sponsor
- Children's Oncology Group
Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7)
Vorinostat in Treating Patients With Acute Myeloid Leukemia
Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for their growth. Giving the drug in different ways may kill more cancer cells.
- Conditions
- Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00305773
- Testing
- vorinostat
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
The purpose of this study is to test the safety of vorinostat (Zolinza) and azacitidine (Vidaza) when combined with gemtuzumab ozogamicin (GO) at different dose levels.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT00895934
- Testing
- vorinostat, gemtuzumab ozogamicin, azacitidine
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Acute Promyelocytic Leukemia
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
Subjects have acute promyelocytic leukemia (APL) that has come back (relapsed) after initial treatment or has not gone away with initial therapy.
- Trial name
- NCT00985530
- Testing
- Tamibarotene, Arsenic trioxide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Northwestern University
Acute Myelogenous Leukemia
Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a daily times 3 schedule in…
- Trial name
- NCT00486265
- Testing
- AZD4877
- Where
- 4 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Chronic Ulnar Nerve Injury
Tendon Transfer for Correction of Pinch in Chronic Ulnar Nerve Injury
This prospective study evaluates the outcomes of combined ECRB and APL tendon transfer for restoring pinch function in patients with chronic ulnar nerve injury.
- Trial name
- NCT07434999
- Testing
- Combined ECRB and APL Tendon Transfer
- Where
- Egypt
- Volunteers
- 17 people
- Sponsor
- Sohag University
Relapsed Acute Promyelocytic Leukemia
Proteasome Inhibition in Acute Promyelocytic Leukemia
The clinical outcome of relapsed acute promyelocytic leukemia (APL) is poor with current standard of care approaches. Additionally, standard of care warrants an autologous stem cell transplant to be done once molecular remission…
- Trial name
- PIAPL (NCT01950611)
- Testing
- Bortezomib
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Christian Medical College, Vellore, India
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia
This clinical trial studies the side effects of gemtuzumab ozogamicin and how well it works in treating patients with acute myeloid leukemia.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT01548911
- Testing
- gemtuzumab ozogamicin, laboratory biomarker analysis
- Sponsor
- Wake Forest University Health Sciences